menu
    • menu
    [{"orgOrder":0,"company":"Adovate","sponsor":"Adial Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"ADO-5030","moa":"A2BR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Adovate","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Adovate \/ Adovate","highestDevelopmentStatusID":"6","companyTruncated":"Adovate \/ Adovate"},{"orgOrder":0,"company":"Adovate","sponsor":"University of Virginia","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ADO-5030","moa":"A2BR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Adovate","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adovate \/ University of Virginia","highestDevelopmentStatusID":"6","companyTruncated":"Adovate \/ University of Virginia"}]

    Find Clinical Drug Pipeline Developments & Deals by Adovate

    Menu

    Adovate

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Adovate

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Adovate

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADO-5030

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : University of Virginia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ADO-5030 in Bronchoconstriction Challenge, Phase 1b

                            Details : ADO-5030 is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Asthma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 15, 2025

                            Lead Product(s) : ADO-5030

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : University of Virginia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Adovate

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Adovate

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADO-5030

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Recipient : Adial Pharmaceuticals

                            Deal Size : $83.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Adial Pharma gets Milestone Payment from Adovate After Phase 1 Study Start

                            Details : Under the agreement, the ADO-5030 compound is being developed by Adovate as a potential first-line therapy for asthma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $0.4 million

                            May 13, 2025

                            Lead Product(s) : ADO-5030

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Recipient : Adial Pharmaceuticals

                            Deal Size : $83.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.